Abstract:Abstract Background In the ATN ( A myloid b, T au, N eurodegeneration) biomarker research framework proposed for Alzheimer’s Disease (AD), a critical need is the identification of robust markers of neurodegeneration (“N”) for more accurate disease state diagnosis and prognosis. Targeted proteomic profiling can be highly valuable for identifying such markers. Method We reanalyzed OlinkTM data from 270 CSF and plasma samples from the Swedish BioFINDER study (Whelan et al. 2019) using additional normalization and adjustments to reduce technical variation and inter‐subject heterogeneity. These include 1) plate‐level quantile normalization, 2) adjustment for age, gender, BMI, and anti‐inflammatory drugs, and 3) first principal component as a covariate to account for heterogeneity in control subjects from different cohorts. Our analysis cohort included 140 Aβ+ cognitively normal (ApCN), 65 Aβ+ mild cognitive impairment (ApMCI), and 138 Aβ + AD (ApAD) subjects. Proteins with false discovery rate < 5% and Cohen’s D ≥ 0.5 were considered statistically significant. Multiscale Embedded Gene Co‐expression Network Analysis (MEGENA) was used to identify co‐expressing network modules and hub proteins. Result Our analysis identified significant alterations of 65 CSF and 94 plasma proteins comparing different pairs of ApAD, ApMCI and ApCN groups. AUC ranged from 61% to 86% for differentiating ApAD vs ApCN. MMP‐10 was found to be significantly altered in all CSF comparisons, but not in plasma. We identified many significantly altered proteins not reported by Whelan et al (2019), including TFF3, EFNA4, and CTSC that are known to be associated with neurodegeneration or neuroinflammation. MEGENA analysis identified 10 network modules for CSF and 17 network modules for plasma. The most significant CSF modules were represented by IGFB‐2 and PLC hub proteins and enriched for positive regulation of cellular function. The most significant plasma modules were represented by SIRT2 and LAT and enriched for cellular response to stimulus. Conclusion Targeted proteomic profiling of matching CSF and plasma samples along with co‐expression network analysis can yield additional markers in the ATN framework for early detection and screening for AD.

Novel Insight in Idiopathic Normal Pressure Hydrocephalus (iNPH) Biomarker Discovery in CSF

Identification of Candidate Biomarkers of Alzheimer's Disease Via Multiplex Cerebrospinal Fluid and Serum Proteomics.

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Molecular Signatures of Normal Pressure Hydrocephalus: A Large-scale Proteomic Analysis of Cerebrospinal Fluid

Cerebrospinal Fluid Biomarkers in Idiopathic Normal Pressure Hydrocephalus

In Vivo Prevalence of Beta-Amyloid Pathology and Alzheimer's Disease Co-Pathology in Idiopathic Normal-Pressure Hydrocephalus—Association with Neuropsychological Features

Radiological Biomarkers of Idiopathic Normal Pressure Hydrocephalus: New Approaches for Detecting Concomitant Alzheimer's Disease and Predicting Prognosis

Profiling iNPH features through cluster analysis: an aid for clinical suspicion and diagnosis

Cerebrospinal fluid biomarkers that reflect clinical symptoms in idiopathic normal pressure hydrocephalus patients

Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases

Forget About Memory: Disentangling the Amnestic Syndrome in Idiopathic Normal Pressure Hydrocephalus

Interplay between vascular hemodynamics and the glymphatic system in the pathogenesis of idiopathic normal pressure hydrocephalus, exploring novel neuroimaging diagnostics

Diagnosis and treatment for normal pressure hydrocephalus: From biomarkers identification to outcome improvement with combination therapy

Targeted proteomic profiling in cerebrospinal fluid and plasma identifies biomarkers for Alzheimer’s disease

Current research of idiopathic normal pressure hydrocephalus: Pathogenesis, diagnosis and treatment

Can Small Molecules Provide Clues on Disease Progression in Cerebrospinal Fluid from Mild Cognitive Impairment and Alzheimer’s Disease Patients?

Blood-brain barrier-associated biomarker correlated with cerebral small vessel disease and shunt outcome in normal pressure hydrocephalus: a prospective cohort study

Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis

Abnormal Characteristic Static and Dynamic Functional Network Connectivity in Idiopathic Normal Pressure Hydrocephalus.

Cerebrospinal Fluid Prongf: A Putative Biomarker for Early Alzheimer's Disease.

Imaging Markers for Normal Pressure Hydrocephalus: An Overview